Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know

Morningstar

Trupanion

If you're putting together a list of overlooked AI stocks, I wouldn't try to sneak Nvidia (NASDAQ: NVDA ) on it. Even investor neophytes know about CEO Jensen Huang's obsession with artificial intelligence ( AI ) and generative AI at the enterprise level.

3 Stealth AI Stocks That Everyone Is Overlooking

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Lantheus Holdings (LNTH): Should You Buy?

Terran Orbital Corp

UiPath

Artificial intelligence is still all the rage with investors, but the hype has pushed many stocks to unsustainable heights. Now that the irrational frenzy is cooling off, some compelling opportunities are emerging away from the hot spotlight.

3 AI Stocks That Should Be on Every Investor's Radar This Fall

Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Lantheus Holdings (LNTH): Can Its 6.4% Jump Turn into More Strength?

Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think Lantheus Holdings (LNTH) Is a Good Investment: Is It?

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria.

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

Investors need to pay close attention to Lantheus Holdings (LNTH) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Lantheus Holdings (LNTH) Stock?

Radiopharmacy is expected to experience exponential growth over the next decade. Radiopharmaceutical-based therapies offer more targeted and specific approaches for cancer treatment and medical imaging, with prostate cancer proving to be a particularly fertile ground for this tech. Lantheus Holdings' flagship product, PYLARIFY, has shown promising results in prostate cancer imaging and diagnosis.

Lantheus: Not Quite Ready To Take The Plunge

Zacks.com users have recently been watching Lantheus Holdings (LNTH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know

Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Yuan Zhi - B. Riley Richard Newitter - Truist Securities Matt Taylor - Jeffries Anthony Petrone - Mizuho Americas Justin Walsh - Jones Trading Larry Solow - CJS David Turkaly - JMP Securities Operator Good morning.

Lantheus Holdings, Inc. (LNTH) Q2 2023 Earnings Call Transcript

Lantheus Holdings (LNTH) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.89 per share a year ago.

Lantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue Estimates

Agreement enhances Lantheus' strong liquidity position and supports continued pipeline advancement and commercial readiness Agreement enhances Lantheus' strong liquidity position and supports continued pipeline advancement and commercial readiness

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today reported financial results for its second quarter ended June 30, 2023.

Lantheus Reports Second Quarter 2023 Financial Results

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023, to discuss its financial and operating results for the second quarter of 2023.

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time

Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?

I last wrote about Lantheus ( LNTH ) as the Bull of the Day in March after their stunning Q4'22 report that caught Wall Street off-guard and moved estimates significantly higher. Well the company just did it again with their Q1 report that delivered another beat-and-raise in May, and drove shares to new all-time highs.

Bull of the Day: Lantheus (LNTH)

Kinsale Capital Group

Wingstop

Mid-cap stocks sometimes don't receive much attention, as many are fixated on small-caps' explosive growth characteristics and large-caps' stable natures.

3 Top-Ranked Mid-Caps With Big Growth

Chipotle

eGain

Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns

Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes it likely that Lantheus' stock outperforms over the long term.

Lantheus: Pylarify And Definity Driving Strong Growth

BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at the upcoming 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which will be held June 24-27, 2023 in Chicago, Illinois.

Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

GE HealthCare Technologies Inc

After soaring this year, shares of Nano-X are looking a bit rich. Lantheus has a product that helps detect the presence of prostate cancer.

2 Medical Imaging Stocks That Are Better Buys Than Nano-X

Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News for Lantheus Holdings Stock (LNTH)